Lumexa Imaging Holdings, Inc. (LMRI)
Compare with another name Open in your desk ↗
Lumexa Imaging Holdings, Inc. (LMRI) reported revenue of $264 million for Q2 FY2026, the quarter ended 30 June 2026, up 5.1% on the same quarter a year earlier. Net income was $3 million, and diluted earnings per share $0.03. The figures are the company's own, from the 10-Q it filed with the SEC on 13 August 2026.
Revenue$264 millionup 5.1%
Net income$3 million
Diluted EPS$0.03
QuarterQ2 FY2026ended 30 June 2026
Lumexa Imaging Holdings (LMRI) in brief
Lumexa Imaging Holdings had 96 million shares outstanding at the latest filed count.
Read more
At 30 June 2026 it carried $835 million of debt and $70 million of cash. At the close of 30 October 2026 the market cap of Lumexa Imaging Holdings was $1.1 billion.Ratios
From the filings
ROEn/a
ROCEn/a
Operating marginn/a
Net marginn/a
FCF marginn/a
Interest covern/a
Debt to equity1.36
Cash conversionn/a
Share count, last 12 months0.0%
Sales CAGR, 3 yearsn/a
Profit CAGR, 3 yearsn/a
EPS, TTMn/a
At the close of 30 October 2026
Price$11.40
Market cap$1.1 billion
Stock P/En/a
Price to book1.78
EV / EBITDAn/a
Dividend yieldn/a
Market cap / salesn/a
52-week high$18.53
52-week low$6.77
Price, 1 yearn/a
Price CAGR, 3 yearsn/a
Price CAGR, 5 yearsn/a
Worked from the filed figures; hover a name for the formula.
Read more
The priced ones use the latest price, the last regular-hours trade on IEX. Debt to equity here stands on long-term debt as Lumexa Imaging Holdings, Inc. files it, with lease liabilities counted separately and never inside it. Nothing here is a valuation or a view.LMRIgreeksoup.ai
Daily prices to 30 October 2026, adjusted for splits; from 28 September 2026 each day's price is the last regular-hours trade on IEX.
Read more
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. Day by day for the last three years; before that one point a week, carrying the week's last close and its average daily volume, so a volume bar means the same thing across the whole series; the bars sit under the price on their own scale, on the right. The moving averages need consecutive days and are drawn from the daily part. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Before the quarters on file begin, P/E, price to book and market cap to sales stand on each annual report from the day it was filed. Drawn in your browser; the range and overlay you pick are remembered here only.The public record on LMRI
| Filings | 17 in twelve months: 10 current reports (8-K), about 5 regulation FD disclosure; 4 results of operations; 3 material agreement; 2 new financial obligation; 2 officer or director change |
| Planned insider sales | no Form 144 notice in twelve months |
| Options tape | no listed options |
| 13F holders | 102 funds reported a position for the quarter to 30 June 2026; largest Brown Advisory Inc. |
| Insider trading | 0 sales and 2 purchases on Form 4 in twelve months |
| Congress | 0 House trades disclosed in six months |
| Short interest | 1.9 million shares short, 5.63 days to cover at 15 October 2026 |
| Documents | the 10-K, the 10-Qs, the proxy and 4 earnings press releases, each linked |
Quarterly results, the last 4 quarters
| Q1 FY2025 | Q2 FY2025 | Q1 FY2026 | Q2 FY2026 | |
|---|---|---|---|---|
| Revenue | 245 | 251 | 253 | 264 |
| Operating income | 25.5 | 27.7 | 19.4 | 23.0 |
| Operating margin | 10% | 11% | 8% | 9% |
| Interest expense | 29.8 | 30.1 | 16.3 | 16.2 |
| Pre-tax income | -4.3 | -2.4 | 3.1 | 5.8 |
| Tax rate | n/a | n/a | 44% | 52% |
| Net income | -7.7 | -7.2 | 1.7 | 2.7 |
| Net margin | -3% | -3% | 1% | 1% |
| Diluted EPS | -$0.11 | -$0.10 | $0.02 | $0.03 |
| Operating cash flow | -14.0 | 2.1 | 2.9 | 32.8 |
| Capital expenditure | 1.0 | 4.6 | 5.3 | 9.7 |
| Free cash flow | -15.0 | -2.5 | -2.4 | 23.1 |
| Shares outstanding | 96m | 96m | 96m | 96m |
| Filing | 10-Q | 10-Q | 10-Q | 10-Q |
Each quarter as filed, linked to its filing.
Read more
Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.Questions
What is Lumexa Imaging Holdings' market cap?
The market cap of Lumexa Imaging Holdings was $1.1 billion at the close of 30 October 2026.
How much debt does Lumexa Imaging Holdings have?
At 30 June 2026 Lumexa Imaging Holdings carried $835 million of debt and $70 million of cash.
Peers: Healthcare
| Company | Market cap | P/E | ROE | Op. margin | Sales growth TTM | Debt to equity | Div. yield |
|---|---|---|---|---|---|---|---|
| Natera, Inc. NTRA | $59.5 billion | n/a | -10.6% | -10.7% | 37.8% | 0.04 | n/a |
| Labcorp Holdings Inc. LH | $29.4 billion | 29.68 | 11.3% | 10.3% | 6.0% | 0.66 | 0.8% |
| Quest Diagnostics Inc. DGX | $27.7 billion | 25.08 | 14.8% | 14.6% | 9.1% | 0.73 | 1.3% |
| Guardant Health, Inc. GH | $23.9 billion | n/a | n/a | -39.7% | 42.7% | n/a | n/a |
| Caris Life Sciences, Inc. CAI | $9.7 billion | 95.33 | 17.8% | 15.5% | n/a | 0.66 | n/a |
| Grail, Inc. GRAL | $6.4 billion | n/a | -15.4% | -338.4% | 23.1% | 0.00 | n/a |
| RadNet, Inc. RDNT | $5.8 billion | n/a | -1.9% | 3.1% | 18.9% | 1.22 | n/a |
| BillionToOne, Inc. BLLN | $5.3 billion | 129.90 | 7.0% | 10.9% | n/a | 0.17 | n/a |
| CareDx, Inc. CDNA | $4.6 billion | 36.55 | 27.5% | 23.4% | 38.9% | 0.00 | n/a |
| Veracyte, Inc. VCYT | $4.0 billion | 35.45 | 8.2% | 18.8% | 17.3% | 0.00 | n/a |
| Fortrea Holdings Inc. FTRE | $2.1 billion | n/a | -12.9% | 0.5% | -3.4% | 1.98 | n/a |
| Personalis, Inc. PSNL | $1.7 billion | n/a | -45.6% | -164.1% | -13.3% | n/a | n/a |
All 59 in Healthcare
| Company | Market cap | P/E | ROE | Op. margin | Sales growth TTM | Debt to equity | Div. yield |
|---|---|---|---|---|---|---|---|
| HCA Healthcare, Inc. HCA | $99.8 billion | 15.68 | n/a | 12.5% | 5.8% | n/a | 0.6% |
| Natera, Inc. NTRA | $59.5 billion | n/a | -10.6% | -10.7% | 37.8% | 0.04 | n/a |
| Labcorp Holdings Inc. LH | $29.4 billion | 29.68 | 11.3% | 10.3% | 6.0% | 0.66 | 0.8% |
| Quest Diagnostics Inc. DGX | $27.7 billion | 25.08 | 14.8% | 14.6% | 9.1% | 0.73 | 1.3% |
| Guardant Health, Inc. GH | $23.9 billion | n/a | n/a | -39.7% | 42.7% | n/a | n/a |
| Tenet Healthcare Corp. THC | $21.7 billion | 7.92 | 53.3% | 24.4% | 6.2% | 2.43 | n/a |
| Encompass Health Corp. EHC | $13.4 billion | 22.14 | 23.9% | 18.0% | 9.5% | 1.01 | 0.6% |
| BrightSpring Health Services, Inc. BTSG | $13.3 billion | n/a | n/a | n/a | n/a | 1.00 | n/a |
| Davita Inc. DVA | $11.9 billion | 13.82 | n/a | 15.0% | 6.4% | n/a | n/a |
| Ensign Group, Inc. ENSG | $10.6 billion | 27.03 | 15.6% | 9.0% | 17.5% | 0.08 | 0.1% |
| Universal Health Services Inc. UHS | $10.4 billion | 7.17 | 20.3% | 11.4% | 10.0% | 0.65 | 0.5% |
| Caris Life Sciences, Inc. CAI | $9.7 billion | 95.33 | 17.8% | 15.5% | n/a | 0.66 | n/a |
| Pacs Group, Inc. PACS | $7.6 billion | 28.61 | 24.2% | 7.4% | 16.6% | 0.22 | n/a |
| Chemed Corp. CHE | $7.0 billion | 25.59 | 32.8% | 13.9% | 5.2% | 0.27 | 0.5% |
| Hims & Hers Health, Inc. HIMS | $6.5 billion | n/a | -43.8% | -6.0% | 28.0% | 4.21 | n/a |
| Grail, Inc. GRAL | $6.4 billion | n/a | -15.4% | -338.4% | 23.1% | 0.00 | n/a |
| RadNet, Inc. RDNT | $5.8 billion | n/a | -1.9% | 3.1% | 18.9% | 1.22 | n/a |
| BillionToOne, Inc. BLLN | $5.3 billion | 129.90 | 7.0% | 10.9% | n/a | 0.17 | n/a |
| Sotera Health Co. SHC | $5.2 billion | 31.81 | 24.6% | n/a | 8.1% | 3.21 | n/a |
| Concentra Group Holdings Parent, Inc. CON | $5.2 billion | 26.08 | 41.7% | 16.4% | 14.0% | 3.30 | 0.6% |
| LifeStance Health Group, Inc. LFST | $5.1 billion | 103.15 | 3.4% | 4.9% | 20.4% | 0.19 | n/a |
| Option Care Health, Inc. OPCH | $4.8 billion | 23.94 | 16.6% | 5.9% | 5.9% | 0.92 | n/a |
| CareDx, Inc. CDNA | $4.6 billion | 36.55 | 27.5% | 23.4% | 38.9% | 0.00 | n/a |
| Veracyte, Inc. VCYT | $4.0 billion | 35.45 | 8.2% | 18.8% | 17.3% | 0.00 | n/a |
| National Healthcare Corp. NHC | $3.2 billion | 23.11 | 12.5% | 9.3% | 6.9% | 0.00 | 1.3% |
| Surgery Partners, Inc. SGRY | $3.0 billion | n/a | -5.3% | 11.4% | 4.0% | 2.25 | n/a |
| Aveanna Healthcare Holdings, Inc. AVAH | $2.9 billion | 10.70 | 95.6% | 10.5% | 19.5% | 4.52 | n/a |
| Acadia Healthcare Company, Inc. ACHC | $2.7 billion | n/a | -56.9% | -32.6% | 4.3% | 1.22 | n/a |
| Privia Health Group, Inc. PRVA | $2.7 billion | 102.29 | 3.6% | 1.9% | 24.1% | 0.00 | n/a |
| Brookdale Senior Living Inc. BKD | $2.5 billion | n/a | n/a | 3.5% | -4.4% | n/a | n/a |
| Addus HomeCare Corp. ADUS | $2.3 billion | 22.00 | 9.2% | 10.0% | 15.9% | 0.05 | n/a |
| Pediatrix Medical Group, Inc. MD | $2.3 billion | 16.20 | 17.7% | 10.9% | 1.9% | 0.68 | n/a |
| Progyny, Inc. PGNY | $2.3 billion | 31.76 | 17.3% | 8.6% | 5.5% | 0.00 | n/a |
| GeneDx Holdings Corp. WGS | $2.1 billion | n/a | -43.5% | -20.3% | 25.4% | 0.41 | n/a |
| Fortrea Holdings Inc. FTRE | $2.1 billion | n/a | -12.9% | 0.5% | -3.4% | 1.98 | n/a |
| Ardent Health, Inc. ARDT | $1.7 billion | 21.85 | 5.8% | 3.2% | 3.3% | 0.82 | n/a |
| Personalis, Inc. PSNL | $1.7 billion | n/a | -45.6% | -164.1% | -13.3% | n/a | n/a |
| Healthcare Services Group Inc. HCSG | $1.7 billion | 16.46 | 19.7% | n/a | 4.0% | 0.00 | n/a |
| Sonida Senior Living, Inc. SNDA | $1.6 billion | n/a | -14.2% | -13.6% | 49.4% | 1.82 | n/a |
| Teladoc Health, Inc. TDOC | $1.6 billion | n/a | -12.0% | -6.6% | -2.4% | 0.77 | n/a |
| Pennant Group, Inc. PNTG | $1.5 billion | 46.33 | 8.0% | 5.6% | 37.9% | 0.49 | n/a |
| agilon health, Inc. AGL | $1.4 billion | 26.01 | -102.1% | -5.2% | 0.3% | 0.13 | n/a |
| U S Physical Therapy Inc. USPH | $1.3 billion | 96.90 | 7.2% | 9.4% | 11.3% | 0.49 | 2.1% |
| InnovAge Holding Corp. INNV | $1.2 billion | n/a | -1.1% | 0.3% | 15.9% | 0.21 | n/a |
| Omada Health, Inc. OMDA | $1.1 billion | 375.10 | 1.7% | -0.1% | n/a | 0.00 | n/a |
| Castle Biosciences Inc. CSTL | $1.1 billion | n/a | -4.1% | -9.0% | 3.2% | 0.02 | 0.0% |
| Lumexa Imaging Holdings, Inc. LMRI | $1.1 billion | n/a | n/a | n/a | n/a | 1.36 | n/a |
| AdaptHealth Corp. AHCO | $791 million | n/a | -16.6% | -4.5% | -0.4% | 1.37 | n/a |
| Starling Oncology, Inc. STLN | $656 million | n/a | n/a | -4.4% | 38.4% | n/a | n/a |
| Fulgent Genetics, Inc. FLGT | $565 million | n/a | -8.4% | -37.7% | 6.8% | 0.00 | n/a |
| SBC Medical Group Holdings Inc. SBC | $541 million | 11.22 | 18.6% | 37.3% | -6.9% | 0.14 | n/a |
| Viemed Healthcare, Inc. VMD | $369 million | 26.89 | 10.1% | 7.5% | 25.2% | 0.05 | n/a |
| Community Health Systems Inc. CYH | $337 million | 9.19 | n/a | 10.9% | -7.8% | n/a | n/a |
| Biodesix Inc. BDSX | $245 million | n/a | -303.6% | -20.0% | 34.5% | 5.47 | n/a |
| Exagen Inc. XGN | $208 million | n/a | -154.9% | -18.6% | 20.8% | 1.87 | n/a |
| Airsculpt Technologies, Inc. AIRS | $123 million | n/a | -11.2% | -8.4% | -8.7% | 0.42 | n/a |
| LifeMD, Inc. LFMD | $110 million | n/a | n/a | n/a | n/a | 0.00 | n/a |
| Sera Prognostics, Inc. SERA | $103 million | n/a | -56.0% | -53,282.9% | -35.2% | 0.00 | n/a |
| Park Dental Partners, Inc. PARK | $99 million | n/a | n/a | n/a | n/a | 0.37 | n/a |
17 companies share its SEC industry code (Services-Medical Laboratories); the rest are the names nearest in size in its wider industry, Healthcare, one of the Fama-French 48 industries, a published grouping of SEC industry codes.